SNORD113-3: A Potential Drug Target and Biomarker (G767563)

Target Name: SNORD113-3

NCBI ID: G767563

SNORD113-3

Other Name(s): Small nucleolar RNA, C/D box 113-3 | 14q(I-3) | small nucleolar RNA, C/D box 113-3

SNORD113-3: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA), also known as microRNA (miRNA), is a non-coding RNA molecule that plays a critical role in regulating gene expression in various organisms, including humans. One of the most well-known snRNAs is SNORD113-3 , which is located in the C/D box 113-3 of the 28S rRNA molecule.

The C/D box is a part of the rRNA molecule that contains a specific sequence that is involved in the formation of double bonds. SNORD113-3 is a small RNA molecule that contains 29 amino acid residues and has a calculated molecular weight of 30.4 kDa . It is expressed in various tissues and cells of the human body and is involved in the regulation of gene expression.

SNORD113-3 has been identified as a potential drug target and biomarker due to its unique structure and its involvement in the regulation of cellular processes.

Potential Drug Target

SNORD113-3 has been shown to play a role in the regulation of cellular processes that are crucial for human health and development. One of the most significant functions of SNORD113-3 is its role in the regulation of apoptosis, which is a natural process that helps the body to eliminate damaged or dysfunctional cells.

Studies have shown that SNORD113-3 is involved in the regulation of apoptosis by promoting the expression of genes that are involved in the formation of the apoptotic machinery. Additionally, SNORD113-3 has been shown to inhibit the expression of genes that are involved in the prevention of apoptosis.

This suggests that SNORD113-3 may be a useful drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases, as these conditions are characterized by the formation of damaged or dysfunctional cells that cannot be eliminated by the body's natural apoptosis mechanisms.

Biomarker

SNORD113-3 has also been identified as a potential biomarker for various diseases. The expression of SNORD113-3 has been shown to be affected by various factors, including gene expression, DNA methylation, and smallRNA interactions.

Studies have shown that the expression of SNORD113-3 is regulated by various factors, including the expression of microRNAs that come from the miRNA pathway. Additionally, SNORD113-3 has been shown to interact with various proteins, including the protein Let-61, which is involved in the regulation of apoptosis.

This suggests that SNORD113-3 may be a useful biomarker for the diagnosis and prognosis of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases, as these conditions may be characterized by changes in the expression of SNORD113-3 and its interactions with other proteins.

Conclusion

SNORD113-3 is a small nucleolar RNA molecule that has unique structure and plays a critical role in the regulation of gene expression in various organisms. Its potential as a drug target and biomarker makes it an attractive target for the development of new therapies for various diseases.

Future studies are needed to fully understand the role of SNORD113-3 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 113-3

The "SNORD113-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD113-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets